Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Moderate Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $24.00.

Several brokerages have recently weighed in on ZVRA. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Zacks Research downgraded shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. HC Wainwright started coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a “buy” rating and a $26.00 target price for the company. JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $9.31 on Friday. Zevra Therapeutics has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The company has a market capitalization of $522.57 million, a price-to-earnings ratio of -44.33 and a beta of 1.49. The firm has a 50-day simple moving average of $9.46 and a 200-day simple moving average of $8.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode acquired 5,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company’s stock, valued at approximately $412,200. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its stake in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Rubric Capital Management LP lifted its stake in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares during the period. BNP Paribas Financial Markets raised its position in Zevra Therapeutics by 1,240.5% during the second quarter. BNP Paribas Financial Markets now owns 42,950 shares of the company’s stock worth $378,000 after acquiring an additional 39,746 shares during the last quarter. Bank of America Corp DE raised its position in Zevra Therapeutics by 150.4% during the second quarter. Bank of America Corp DE now owns 223,852 shares of the company’s stock worth $1,972,000 after acquiring an additional 134,437 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after acquiring an additional 550,000 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.